Arthritis & rheumatology (Hoboken, N.J.)
September 9, 2026 · via Europe PMC
Updated COVID-19 Vaccines and Health Outcomes in Patients With Autoimmune Rheumatic Conditions.
Jackson LE, Anzalone AJ, Saag KG, +7 more, National Clinical Cohort Collaborative Consortium.
AI summary — for doctors, generated from the abstract only
In a large US cohort of patients with autoimmune rheumatic conditions, receiving a booster or updated COVID-19 vaccine was associated with substantially lower odds of COVID-19-related hospitalization compared to the initial vaccine series alone or no vaccination.
What was studied
A retrospective cohort study using National Clinical Cohort Collaborative (N3C) data on 60,980 adults with autoimmune rheumatic conditions who developed COVID-19 between December 2020 and August 2024, assessing the association between COVID-19 vaccination status (unvaccinated, initial series, booster, or updated 2023-2024 vaccine) and COVID-19-related hospitalization, mechanical ventilation/ECMO, and death, using mixed-effects logistic regression adjusted for demographics, clinical risk, social vulnerability, and medications.
Key findings
- Among 60,980 patients (median age 62, 76% female, 74% non-Hispanic White), 10% had received an updated (2023-2024) COVID-19 vaccine.
- Adjusted odds of hospitalization decreased progressively with vaccination: initial series aOR 0.59 (95% CI 0.56-0.63), boosted series aOR 0.29 (95% CI 0.27-0.31), updated series aOR 0.31 (95% CI 0.28-0.34), compared with no vaccine doses.
- Comparing patients who received only the initial series versus a booster/updated vaccine, the absolute risk reduction in hospitalization was 5.6%.
Clinical relevance
The findings suggest that booster or updated COVID-19 vaccination provides substantial additional protection against hospitalization beyond the initial vaccine series for this immunosuppressed/medically vulnerable population, supporting continued encouragement of updated vaccination in patients with autoimmune rheumatic conditions, which is directly actionable for rheumatology clinical practice.
Who should care
Limitations
This is an observational retrospective cohort study, so residual confounding (e.g., healthier patients being more likely to get boosted) cannot be fully excluded despite statistical adjustment; outcomes beyond hospitalization (mechanical ventilation/ECMO, death) were assessed but specific adjusted estimates for those outcomes were not detailed in the provided abstract text.
Updated or booster COVID-19 vaccination substantially reduced the risk of COVID-19 hospitalization in patients with autoimmune rheumatic conditions compared to the initial vaccine series alone or no vaccination.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
Objective
We aimed to assess the association between COVID-19 vaccination status and COVID-19-related hospital admissions, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and death in people with autoimmune rheumatic conditions.
Methods
We conducted a retrospective cohort study using National Clinical Cohort Collaborative (N3C) data on adults with autoimmune rheumatic conditions and incident COVID-19 occurring between December 2020 and August 2024. We assessed the association between COVID-19 vaccination status (unvaccinated, receipt of initial series, booster, or updated [2023-2024] vaccine) and COVID-19-related hospitalization (primary outcome), mechanical ventilation or ECMO, and death. Associations were estimated using mixed-effects logistic regression, adjusting for demographics, clinical risk, social vulnerability, and medications.
Results
Our cohort included 60,980 patients with rheumatic conditions (median age 62 years), of whom 46,043 (76%) were female and 44,876 (74%) were non-Hispanic White. Overall, 6,336 (10%) had received an updated (2023-2024) COVID-19 vaccine. Adjusted odds of hospitalization decreased progressively with vaccination (initial series adjusted odds ratio [aOR] 0.59 [95% confidence interval (CI) 0.56-0.63]; boosted series aOR 0.29 [95% CI 0.27-0.31]; and updated series aOR 0.31 [95% CI 0.28-0.34]) compared with no vaccine doses. Among patients who had received only the initial vaccine series versus a booster/updated vaccine, the absolute risk reduction was 5.6%.
Conclusion
We observed decreased odds of COVID-19-related hospitalizations among patients with autoimmune rheumatic conditions who received an updated COVID-19 or booster vaccine compared to those who received the initial series alone or were unvaccinated. Updated vaccinations provide significant protection for this medically vulnerable population and should be supported by clinicians, policymakers, and patient advocacy groups.
DOI
10.1002/art.70290
PMID
42712104
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed